Tactile Systems Technology Inc

Tactile Systems Technology Inc(TCMD)の株式分析

$23.160

+0.051 (+0.22%)終値時点

Loading chart…
High
23.330
Open
23.260
VWAP
23.07
Vol
304.58K
Mkt Cap
274.93M
Low
22.730
Amount
7.03M
EV/EBITDA, TTM
12.21

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.

AI analysis of Tactile Systems Technology Inc (TCMD)

buy

Tactile Systems Technology Inc is a good buy right now due to its current price of $23.16, which is significantly below the analyst price target of $36, indicating a potential upside of 55%. Additionally, the company has shown strong revenue growth, with Q2 2026 revenue reaching $85.7 million, a 9% year-over-year increase, and gross margins improving to 76.3%. However, the main risk is the recent performance decline, with a 20-day change of -17.78%.

Analyst Ratings (6)

+36.74% upside
Buy
6 Buy
0 Hold
0 Sell
Current: 23.16
安値
28.00
平均
31.67
高値
35.00

B. Riley

2026-05-07

目標株価

$36

Buy

BTIG

2026-05-05

目標株価

$40

Buy

BTIG

2026-02-18

目標株価

$38

Buy

B. Riley

2026-02-18

目標株価

$32

Neutral

Lake Street

2026-02-18

目標株価

$40

Buy

バリュエーション指標

The current forward P/E ratio for Tactile Systems Technology Inc (TCMD) is 19.12, compared to its 5-year average forward P/E of 114.24.

Forward P/E

Fair
5Y Average P/E
114.24
Current P/E
19.12
割高
590.80
割安
-362.32

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-7.08
Current EV/EBITDA
12.21
割高
76.38
割安
-90.53

Forward P/S

Fair
5Y Average P/S
1.29
Current P/S
1.32
割高
1.85
割安
0.72

Alphio AI Price Scenarios for TCMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TCMD

$12.55

シナリオ価格

B

Base

Base · 50%TCMD

$12.06

シナリオ価格

B

Bear

Bear · 25%TCMD

$10.94

シナリオ価格

Whales holding TCMD

N

Next Century Growth Investors LLC

+ HoldingTCMD

-10.44%

3M Return

イベントタイムライン

2026-08-10 (ET)

16:30:00

Tactile Medical Q2 Revenue $85.7M Beats Expectations

2026-05-04 (ET)

16:30:00

Company Updates 2026 Revenue Outlook to $368 Million

16:30:00

Tactile Medical Q1 Revenue $75.27M, Exceeds Expectations

2026-03-09 (ET)

08:30:00

Tactile Systems Appoints Andrea Pearson to Board of Directors

2026-02-17 (ET)

17:00:00

Tactile Systems Acquires LymphaTech for $6.8M

ニュース

TCMD FAQ — answered by Alphio AI

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tactile Systems Technology Inc is a good buy right now due to its current price of $23.16, which is significantly below the analyst price target of $36, indicating a potential upside of 55%. Additionally, the company has shown strong revenue growth, with Q2 2026 revenue reaching $85.7 million, a 9% year-over-year increase, and gross margins improving to 76.3%. However, the main risk is the recent performance decline, with a 20-day change of -17.78%.

6 analysts cover TCMD: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.67.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める